IRIS
BRANCACCIO, Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.144
NA - Nord America 1.608
AS - Asia 1.201
SA - Sud America 406
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 5.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.580
RU - Federazione Russa 812
IE - Irlanda 500
SG - Singapore 456
BR - Brasile 338
GB - Regno Unito 261
CN - Cina 250
HK - Hong Kong 226
UA - Ucraina 123
VN - Vietnam 113
IT - Italia 112
DE - Germania 77
SE - Svezia 57
GR - Grecia 55
FR - Francia 54
KR - Corea 48
AR - Argentina 35
FI - Finlandia 32
TR - Turchia 25
IN - India 18
CZ - Repubblica Ceca 17
MX - Messico 15
BE - Belgio 14
JP - Giappone 14
ID - Indonesia 13
BD - Bangladesh 12
AT - Austria 11
EC - Ecuador 10
ZA - Sudafrica 7
CA - Canada 6
PK - Pakistan 6
BO - Bolivia 5
CO - Colombia 5
ET - Etiopia 5
RO - Romania 5
PE - Perù 4
PL - Polonia 4
PY - Paraguay 4
DZ - Algeria 3
EU - Europa 3
IQ - Iraq 3
MA - Marocco 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CL - Cile 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
KE - Kenya 2
LT - Lituania 2
NI - Nicaragua 2
NP - Nepal 2
UZ - Uzbekistan 2
VE - Venezuela 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EE - Estonia 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 5.389
Salva come PNG Salva come JPEG
Città #
Dublin 500
Moscow 263
Chandler 252
Santa Clara 231
Hong Kong 226
Jacksonville 198
Singapore 174
Dallas 80
Princeton 72
Medford 69
Roxbury 65
Houston 54
Beijing 51
New York 51
Seoul 48
The Dalles 44
Ho Chi Minh City 40
Munich 34
Ashburn 31
Wilmington 27
Caserta 26
São Paulo 24
Ann Arbor 22
Des Moines 22
Hanoi 17
Brno 16
Napoli 15
Brussels 14
Nanjing 13
Los Angeles 11
Boardman 10
Bremen 10
Porto Alegre 10
Belo Horizonte 9
Bengaluru 9
Nuremberg 9
Redwood City 9
Woodbridge 9
Helsinki 8
San Mateo 8
Brasília 7
Campinas 7
Curitiba 7
Mountain View 7
Changsha 6
Haiphong 6
Nanchang 6
Rio de Janeiro 6
Rome 6
Shanghai 6
Cambridge 5
Guadalajara 5
Guarulhos 5
Hefei 5
Milan 5
Ninh Bình 5
Tokyo 5
Turku 5
Atlanta 4
Bagheria 4
Belford Roxo 4
Caxias do Sul 4
Clifton 4
Columbus 4
Jakarta 4
La Paz 4
Lima 4
Ribeirão Preto 4
Santo André 4
São Bernardo do Campo 4
Zhengzhou 4
Aversa 3
Bogotá 3
Can Tho 3
Contagem 3
Duque de Caxias 3
Fairfield 3
Fortaleza 3
Franca 3
Fuzhou 3
Ha Long 3
Jinan 3
Joinville 3
Lahore 3
Padova 3
Praia Grande 3
Quito 3
Salvador 3
Shenyang 3
Sorocaba 3
Stockholm 3
Tianjin 3
Volta Redonda 3
Ankara 2
Aparecida de Goiânia 2
Araucária 2
Baku 2
Barra do Garças 2
Bauru 2
Belém 2
Totale 3.017
Salva come PNG Salva come JPEG
Nome #
Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays 204
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. 126
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study 124
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 122
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 117
AISF position paper on HCV in immunocompromised patients 117
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. 116
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 107
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 106
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 105
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 103
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 101
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 101
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. 99
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 93
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 93
Virological patterns of HCV patients with failure to interferon-free regimens. 92
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 92
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis. 91
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 91
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 89
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 89
Hepatitis delta infection in Italian patients: towards the end of the story? 88
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 88
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. 86
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 85
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 84
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 83
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 82
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 80
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 80
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 77
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 74
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 74
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 74
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 73
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 73
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study. 70
Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin 69
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 69
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 68
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 67
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 66
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 65
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 64
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 63
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 63
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues. 63
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 61
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 60
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 60
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 56
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 56
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 55
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 55
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 54
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 54
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 54
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 51
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 51
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 50
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 50
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 50
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 50
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 48
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 47
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 47
Influenza vaccination in patients with cirrosi and in liver transplant recipients. 44
Salvage therapy with follone by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 44
Platelets and hepatocellular cancer: Bridging the bench to the clinics 43
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 42
Hepatitis C Virus Clearance in Older Adults 40
Totale 5.528
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.424
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.424
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021195 0 0 0 0 0 7 59 18 7 29 61 14
2021/2022510 21 9 12 21 174 8 12 24 25 26 36 142
2022/2023928 79 13 12 78 80 76 2 66 482 6 17 17
2023/2024305 29 8 12 8 115 50 0 7 0 6 14 56
2024/2025984 20 23 8 17 168 116 141 56 155 126 89 65
2025/20261.863 113 162 309 274 364 641 0 0 0 0 0 0
Totale 5.528